跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
recombinant epidermal growth factor
首页
药物
recombinant epidermal growth factor
recombinant epidermal growth factor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Recombinant anti-epidermal growth factor receptor antibody compositions
US 7887805 B2
申请人: SYMPHOGEN AS
优先权: 2007
CN
US
6 件公开
US 2011229463 A1
申请人: SYMPHOGEN AS
优先权: 2009
US
2 件公开
USE OF EPIDERMAL GROWTH FACTOR DEPLETING AGENTS IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
US 2023256069 A1
申请人: CT INMUNOLOGIA MOLECULAR
优先权: 2020
CN
EP
US
3 件公开
Topical burn composition containing Mentha haplocalyx and one or both of Aloe vera and recombinant human epidermal growth factor
US 7438937 B2
申请人: FANG CHANGGE
优先权: 2005
CN
US
3 件公开
Method for improving secretion and production efficiency of human epidermal growth factors by strengthening crimped bacterial hairs of bacteria
CN 116554298 A
申请人: NANJING UNIVERSITY OF TECHNOLOGY
优先权: 2022
CN
3 件公开
Peptabody for cancer treatment
US 2006233808 A1
申请人: DEPERTHES DAVID
优先权: 2003
CN
US
2 件公开
MFG-E8 AND USES THEREOF
US 2014121163 A1
申请人: WANG PING
优先权: 2012
CN
US
2 件公开
Thermostable human epidermal growth factor-spider venom fusion protein with increased skin cell proliferation effect and cosmetic composition for anti-wrinkle and maintaining elasticity of skin comprising the same as effective component
US 10125181 B2
申请人: NEXGEN BIOTECHNOLOGIES INC
优先权: 2016
CN
US
2 件公开
Botulinum toxin-human epidermal growth factor fusion protein with increased skin cell proliferation and anti-oxidation effect and cosmetic composition for regenerating skin and improving skin wrinkle comprising the same as effective component
US 10266817 B2
申请人: NEXGEN BIOTECHNOLOGIES INC
优先权: 2016
CN
US
2 件公开
LENTIVIRAL VECTOR FOR OVEREXPRESSING EGF, RECOMBINANT STEM CELL, AND USE THEREOF
US 20250114481 A1
申请人: CENTRE FOR REGENERATIVE MEDICINE AND HEALTH HONG KONG INST OF SCIENCE & INNOVATION CHINESE
优先权: 2023
CN
US
2 件公开
USE OF DUAL GROWTH FACTOR-LOADED EXOSOME EGF-FGF-EXO AND PREPARATION METHOD THEREFOR
WO 2026144955 A1
申请人: SUZHOU EVMEDICAL CO LTD
优先权: 2024
CN
WO
2 件公开
第 1 / 10 页
上一页
下一页
药物
反馈